MedTrace Logo

Omega 3 Supplementation and Ocular Surface Disease in Glaucoma

NCT01630551 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-02-28

No results posted yet for this study

Summary

Ocular surface disease (OSD) is a significant health problem that affects more than 10 million persons in the United States alone. OSD is highly prevalent among medically treated patients with glaucoma and is associated with the number of intraocular pressure (IOP)-lowering medications used.

The purpose of this study is to determine the potential effectiveness of anoritega-3 fatty acid nutritional supplement in the treatment of ocular surface disease associated"with the use of glaucoma eye drops

Conditions

  • Ocular Surface Disease

Interventions

DIETARY_SUPPLEMENT

Fishoil supplement

1 capsule per day

DIETARY_SUPPLEMENT

Olive Oil

1 capsule per day

Sponsors & Collaborators

  • American Glaucoma Society

    collaborator OTHER

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Ahmad A Aref, MD · University of Illinois at Chicago College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01630551 on ClinicalTrials.gov